Molecular docking studies indicate that cissamaline, cissamanine, and cissamdine interact with key AD-associated proteins—demonstrating potential as inhibitors of Angiotensin-Converting Enzyme (ACE) and β-site APP cleaving enzyme 1 (BACE1) and exhibiting inhibitory characteristics against Glycogen Synthase Kinase-3β (GSK-3β) and Acetylcholinesterase (AChE). This evidence concerns the gene BACE1 and Alzheimer disease.